ReviewACS omega2026
Translational Advances in Chitosan Biomaterials: From Molecular Modification to Clinical Medicine.
Review in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Redox-Regulating Propolis- and Honey-Containing Hydrogels in Osteoarthritis.Antioxidants (Basel, Switzerland) · 2026Review
- Preparation of a Thermosensitive Chitosan-Sea Cucumber Peptide Hydrogel and Its Alleviating Effect on Acute Alcohol-Induced Dual Liver and Brain Injury in Mice.Marine drugs · 2026Article
- Hydrophobically Modified Chitosan in Biomedical Applications: Great Expectations vs. Translational Reality.Polymers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chitosan (CS), a cationic polysaccharide derived from natural sources, has emerged as a critical biomaterial due to its biodegradability, biocompatibility, and antimicrobial properties. The reactive amino and hydroxyl functional groups enable chemical modifications and diverse structural fabrications, expanding applications in drug delivery, wound healing, and tissue engineering. Recent advances include strategic modifications and synergistic approaches that enhance the therapeutic efficacy. However, CS faces limitations, including poor solubility under physiological conditions, inadequate mechanical strength, and thermal instability. To address these challenges, innovative strategies involving chemical modifications and advanced material engineering have been developed. This review examines strategic advancements in CS-based medical materials over the past five years, focusing on material preparation innovations and disease treatment mechanisms, providing insights into CS's transformative potential in sustainable healthcare solutions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.